ProVee System for BPH
Proverum, Ltd. · Decision date Nov 3, 2026
What did the FDA approve?
The FDA recorded an approval decision dated 2026-11-03 for P250011/S005, a PMA supplement to the ProVee System for BPH submitted by Proverum, Ltd. The supplement is classified as a Real-Time Process review with the stated reason Change Design/Components/Specifications/Material. The recorded statement identifies the changed item as changes to the OmniVision CMOS Camera Cube.
This action covers the supplement only; it is not a new approval of the entire ProVee System. The device category is listed as a permanent or semi-permanent prostatic urethral stent, with Gastroenterology and Urology as the specialty and product code MER. The source record includes no supporting documents, so the scope of the camera cube change, its effect on the finished device, and any conditions of approval remain unknown.
FDA approval order statement
changes to the OmniVision CMOS Camera Cube
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Nov 3, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250011/S005
- Regulatory pathway
- PMA supplement
- Applicant
- Proverum, Ltd.
- Product code
- MER
- Decision code
- APPR
- Decision date
- Nov 3, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: STENT, URETHRAL, PROSTATIC, PERMANENT OR SEMI-PERMANENT.
- Applicant
- Proverum, Ltd.
- Product code
- MER
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250011. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250011 · Original PMA
ProVee System for BPH
P250011/S005 received
Application receipt date recorded by FDA.
P250011/S006 · Related supplement
ProVee System for BPH
P250011/S005 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P250011. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250011
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ProVee System for BPHP250011 | Proverum, Ltd. | PMA approval | Dec 9, 2025 | FDA |
ProVee System for BPHP250011/S006 | Proverum, Ltd. | PMA supplement | Sep 24, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Proverum, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2nd Floor Astor Hall, 4-8 Eden Quay, Dublin, D01N5W8
Sources and methodology
- Original FDA record: P250011/S005
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
